Results 51 to 60 of about 2,399 (178)

Efficient Scaling up EV‐AAVs Production via Cellular Nanoporation for Familial Hypercholesterolaemia Therapy

Journal of Extracellular Vesicles, Volume 14, Issue 11, November 2025.
ABSTRACT Adeno‐associated virus (AAV)–mediated gene therapies face critical clinical limitations, including immune‐mediated neutralization by pre‐existing antibodies and dose‐dependent hepatotoxicity. Extracellular vesicle‐encapsulated AAVs (EV‐AAVs) offer a promising solution by shielding AAVs from antibody recognition, yet existing production methods
Yuting Yan, Yi You, Shuhong Ma, Hui Yi, Guangduo Chen, Jie Ni, Changyan Chen, Wenyu Ke, Lingying Li, Rui Bai, Yuqing Ran, Wenjing Lu, Min Zhu, Yongshuai Zhang, Jing Dai, Man Qi, Feng Lan, Andrew S. Lee, Ran Zhang, Xujie Liu, Zhaoyang Chen   +20 more
wiley   +1 more source

Impact of LDL-Apheresis on inflammation and microcirculation

Atherosclerosis Supplements, 2009
Lipid-apheresis (LIPID-A) is highly effective in reduction of pro-atherosclerotic LDL-cholesterol and lipoprotein (a). It has been demonstrated in prospective and retrospective analyses to reduce major cardiovascular events. In addition to improvement of pro-atherosclerotic lipoprotein milieu, LIPID-A exerts pleiotropic effects on inflammation and ...
Koziolek, Michael J., Mueller, Gerhard A.   +1 more
openaire   +3 more sources

Platelet aggregation and lipoprotein levels in a patient with familial hypercholescholesterolemia after selective LDL-apheresis

São Paulo Medical Journal
Platelet aggregation was studied in a patient with familial hypercholesterolemia immediately after aphereis selective for low-density lipoprotein (LDL), a lipid-lowering procedure.This treatment reduced plasmatic levels of total and LDL-cholesterol, apo ...
Madalena Nunes da Silva Pares, Elbio Antonio D'Amico, José Mauro Kutner, Dalton de Alencar Fischer Chamone, Sergio Paulo Bydlowski   +4 more
doaj   +1 more source

Effects of weekly LDL-apheresis on metabolic parameters of apolipoprotein B in heterozygous familial hypercholesterolemia

Journal of Lipid Research, 1996
Apheresis is a treatment option for patients with severe hypercholesterolemia and coronary artery disease. It is, however, unknown whether such therapy changes kinetic parameters of lipoprotein metabolism, such as apolipoprotein B (apoB) secretion rates,
K G Parhofer, P H Barrett, T Demant, W O Richter, P Schwandt   +4 more
doaj   +1 more source

Comparison of Model‐Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 11, Page 1835-1847, November 2025.
ABSTRACT Evinacumab, an angiopoietin‐like 3 inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH). Herein, we report pharmacokinetic and efficacy analyses of evinacumab in < 5‐year‐old patients with HoFH.
Sébastien Bihorel, Robert Dingman, Jeanne Mendell, Katy C. Norman, Richard T. George, Xue‐Qiao Zhao, Robert Pordy, Daniel Garcia, Wendy S. Putnam, Geetha Raghuveer, Brian W. McCrindle, Elena Fornari, Ivo Baric, Shubha Srinivasan, Melissa Diamond, Eliot A. Brinton, John D. Davis, A. Thomas DiCioccio, Lutz Harnisch   +18 more
wiley   +1 more source

Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications

Diabetes, Obesity and Metabolism, Volume 27, Issue S8, Page 34-46, September 2025.
Abstract Lipoprotein(a) [Lp(a)] is a genetically determined, causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease (CAVD). Despite robust evidence from epidemiological and genetic studies, Lp(a) remains underrecognised in clinical practice due to challenges in measurement, lack of guideline familiarity ...
Alexander C. Razavi, Harpreet S. Bhatia, Roger S. Blumenthal, Michael D. Shapiro, Anurag Mehta   +4 more
wiley   +1 more source

Low-density lipoprotein apheresis shows a rapid response to proteinuria due to C3 glomerulonephritis: a case report and literature review

Renal Replacement Therapy
Background C3 glomerulonephritis (C3GN) is a rare renal disorder caused by dysregulation of the alternative complement pathway, resulting in abnormal C3 activation and deposition.
Hideki Matsumura, Yuko Fujii, Tomoko Tanaka, Maki Kagitani, Akira Ashida   +4 more
doaj   +1 more source

Rheocarna treatment for non‐dialysis patients

Therapeutic Apheresis and Dialysis, Volume 29, Issue 4, Page 588-592, August 2025.
Abstract Introduction Rheocarna has attracted attention as an alternative therapy for severe chronic limb‐threatening ischemia, and there have been reports of its usefulness. However, most of these reports have been on dialysis patients, and there are few reports on the treatment conditions and efficacy in non‐dialysis patients.
Atsushi Ohkubo, Takatoshi Sakurasawa, Yuki Hoshikawa, Masaya Deushi, Mana Usui, Shigeto Komori, Ayako Itagaki, Hiroko Yamamoto, Hiroshi Seshima, Naoki Kurashima, Soichiro Iimori, Shotaro Naito   +11 more
wiley   +1 more source

Coronary Plaque Characteristics Assessed by Optical Coherence Tomography and Plasma Lipoprotein(a) Levels in Patients With Acute Coronary Syndrome

Catheterization and Cardiovascular Interventions, Volume 106, Issue 1, Page 64-72, July 1, 2025.
ABSTRACT Background Lipoprotein(a) [Lp(a)] is associated with increased cardiovascular risk, but its influence on plaque characteristics at optical coherence tomography (OCT) evaluation is not fully understood. Aims This study seeks to explore the impact of Lp(a) levels on plaque morphology as assessed by OCT in a very high‐risk subset of patients ...
Francesca Maria Di Muro, Maria Federica Crociani, Giulia Nardi, Niccolo' Ciardetti, Lucrezia Biagiotti, Elisa Bigi, Francesco Meucci, Miroslava Stolcova, Francesca Ristalli, Emanuele Cecchi, Iacopo Muraca, Renato Valenti, Carlo Di Mario, Alessio Mattesini   +13 more
wiley   +1 more source

Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia

Journal of Lipid Research, 1997
Apheresis only partially controls raised low density lipoprotein cholesterol levels in patients with homozygous familial hypercholesterolemia, who usually respond poorly to lipid-lowering drugs.
A D Marais, R P Naoumova, J C Firth, C Penny, C K Neuwirth, G R Thompson   +5 more
doaj   +1 more source